Viking Therapeutics (VKTX) Earns Daily Media Sentiment Score of 0.14
News coverage about Viking Therapeutics (NASDAQ:VKTX) has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Viking Therapeutics earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.1172948602115 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news headlines that may have impacted Accern Sentiment’s rankings:
- Technical Secrets – Viking Therapeutics, Inc. (NASDAQ: VKTX) – Alpha Beta Stock (alphabetastock.com)
- Viking Therapeutics, Inc. (VKTX) Investors’ React on Long-Term Obligation – Stock News Stop (stockmarketstop.com)
- Viking Therapeutics, Inc. (NASDAQ:VKTX) – Glowing Stock’s Review – Nasdaq Journal (press release) (nasdaqjournal.com)
- Viking Therapeutics to Present at Biotech Showcase 2018 (prnewswire.com)
Shares of Viking Therapeutics (VKTX) traded up $0.01 during mid-day trading on Monday, hitting $5.01. 806,000 shares of the company were exchanged, compared to its average volume of 1,122,300. The firm has a market capitalization of $146.40 and a P/E ratio of -5.89. Viking Therapeutics has a 12-month low of $0.88 and a 12-month high of $5.19.
VKTX has been the subject of several research reports. Maxim Group restated a “buy” rating and issued a $5.00 price target on shares of Viking Therapeutics in a research note on Monday, September 11th. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Viking Therapeutics in a research note on Friday, November 10th. Roth Capital initiated coverage on shares of Viking Therapeutics in a research note on Tuesday, November 21st. They issued a “buy” rating and a $5.00 price target for the company. Finally, ValuEngine downgraded shares of Viking Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://theolympiareport.com/2018/01/08/viking-therapeutics-vktx-earns-daily-media-sentiment-score-of-0-14.html.
About Viking Therapeutics
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.